Videos

Robert Mancini, PharmD, reviews pharmacists’ pivotal role in operationalizing use of bispecifics in diffuse large B-cell lymphoma (DLBCL), overcoming challenges, and supporting direct patient care teams.

A growing number of adult and pediatric patients are being diagnosed with type 2 diabetes, despite increases in care modalities.

A panel of experts share insights on overcoming challenges in responsible opioid prescribing and explore emotional responses, aversion to change, and the role of interdisciplinary collaboration in addressing the opioid crisis.

Stephanie Abel, PharmD, BCPS, and Megan Mitchell, PharmD, MS, discuss pharmacist roles in combating biases, fostering collaboration with prescribers, and implementing strategies for effective opioid stewardship.

Kristen Peterson, PharmD, BCOP, explores how pharmacists deliver comprehensive education, empower patients, manage adverse effects, and prioritize outcomes for multiple myeloma care, ensuring quality treatment understanding and adherence.

Pharmacists discuss emerging therapies, challenges, and pharmacists’ vital role in myelofibrosis patient care, emphasizing disease-modifying agents and care team collaboration.

Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.

Experts discuss patient advocacy, empowering patients in accessing treatments, educating them about health care systems, and collaborating with health care providers for better myelofibrosis management.

Two directors of outpatient services at Allegheny Health Network highlight the significance of Meds-to-Beds in promoting medication adherence while improving patient experience.

Providers can consider the patient’s medication history, comorbidities, or migraine type to help choose a first line treatment or refer the patient to specialized care.

Experts describe considerations for selecting appropriate patients for treatment with a bispecific antibody, including prior therapies for relapsed or refractory multiple myeloma. Strategies to quickly prepare patients for treatment with a bispecific antibody are also discussed.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Amir Ali, PharmD, BCOP, FHOPA, delve into bispecific antibody treatments, focusing on strategies for patient safety and optimizing care in the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.

Robert Mancini, PharmD, discusses bispecific therapy advancements and strategies to manage adverse effects in diffuse large B-cell lymphoma (DLBCL) care, offering insights on toxicity phases, monitoring, and patient care.

Jennifer Marsh, PharmD, BCCCP, discusses the current standard of care for hepatic encephalopathy, highlighting challenges in treatment, prescription drug coverage, transition of care, and outpatient treatment access.

Gabriella Farkas, MD PhD, addresses the multifaceted role of pharmacists in the mental health and wellness space

Migraine headaches are considered a leading cause of disability around the world.

Experts discuss the nuances of using opioid-related terminology in medical documentation and patient counseling, providing insights on avoiding stigmatizing language, fostering patient trust, and addressing the impact on adherence.

Expert colleagues explore responsible opioid management strategies and discuss addressing biases affecting prescribing practices across demographics and replacing stigmatizing language to improve patient outcomes; they also review practical approaches to creating ethical, equitable, and patient-centered opioid stewardship programs.

Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.

Shawn Griffin, PharmD, BCOP, reviews strategies to tackle socioeconomic challenges in myelofibrosis treatment, covering costs, transportation, language barriers, cultural sensitivity, and patient communication.

Pharmacists discuss tailored patient education approaches, emphasizing key medication details, side effects, and financial aspects critical for myelofibrosis care, optimizing adherence and healthcare outcomes.

Public Health Pharmacist discussed wearable technology and AI assisted technology that was displayed at the 2024 Consumer Electronics Show

Experts discuss the impact of advances in the treatment of multiple myeloma on patient care.

Panelists explore the challenges, implementations, and decision-making processes surrounding bispecific treatments in diffuse large B-cell lymphoma (DLBCL).

Health care experts provide insights into patient education, shared decision-making, and treatment monitoring in diffuse large B-cell lymphoma (DLBCL) therapies, reviewing education strategies and response monitoring.

Kristen Peterson, PharmD, BCOP, discusses how pharmacists optimize quality of life for patients with multiple myeloma, manage treatment adverse effects, and adapt amid health care shortages while staying updated on the latest advancements for comprehensive patient care.

Robert Mancini, PharmD, and Victoria Nachar, PharmD, discuss strategies and resources for smooth inpatient to outpatient transitions in myelofibrosis care, highlighting medication reconciliation, financial assistance, and the need for dedicated support staff.

Experts discuss obstacles faced while transitioning myelofibrosis patients from inpatient to outpatient care, emphasizing communication, access to medication, and the need for standardized medication reconciliation protocols.

Kyle Farina, PharmD, BCPS, BCOP, addresses the multifaceted role of pharmacists in CLL management, including their role in patient care, treatment decision support, and addressing safety considerations.